Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Disease mechanisms

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) represents the most prevalent neurodegenerative disorder and leading cause of dementia worldwide, with its incidence rising dramatically in aging populations. This progressive disease is neuropathologically characterized by extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tau tangles, and chronic neuroinflammation, leading to synaptic dysfunction and neuronal loss. Despite extensive research efforts, the complex and multifactorial nature of AD pathogenesis has prevented the development of truly disease-modifying therapies. Current therapeutic approaches, including recently approved anti-amyloid immunotherapies, demonstrate limited clinical efficacy and significant adverse effects, highlighting the need for alternative treatment strategies. This comprehensive review systematically evaluates recent advances in understanding AD pathophysiology, emphasizing the interplay between genetic risk factors (particularly APOE ε4), proteostasis imbalance, metabolic dysfunction, and neurovascular contributions. We critically analyze emerging diagnostic biomarkers, including novel neuroimaging techniques and cerebrospinal fluid/blood-based biomarkers, that enable earlier and more accurate detection. The review provides an in-depth assessment of both pharmacological interventions (such as tau-targeting therapies, anti-inflammatory agents, and neurotransmitter modulators) and non-pharmacological approaches (including lifestyle modifications and cognitive training). Special attention is given to personalized medicine strategies that account for disease heterogeneity and individual risk profiles. By synthesizing evidence from molecular studies, animal models, and clinical trials, we identify key challenges in therapeutic translation and propose future research directions. Our analysis underscores the importance of multimodal interventions targeting multiple pathological processes simultaneously, combined with early detection methods, to effectively combat this devastating disease. This review aims to provide researchers and clinicians with an updated framework for understanding AD pathogenesis and developing more effective treatment paradigms.

What this study adds

Evidence grade: Low

This review states that current therapies, including recently approved anti-amyloid immunotherapies, have limited clinical efficacy and significant adverse effects, and that no truly disease-modifying therapy exists. It surveys possible future strategies such as tau-targeting and anti-inflammatory agents but does not report a proven treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zhang, J., Kong, G., Yang, J., Pang, L., & Li, X. (2025). Pathological mechanisms and treatment progression of Alzheimer’s disease. European journal of medical research. https://doi.org/10.1186/s40001-025-02886-9

Vancouver

Zhang J, Kong G, Yang J, Pang L, Li X. Pathological mechanisms and treatment progression of Alzheimer’s disease. European journal of medical research. 2025. doi:10.1186/s40001-025-02886-9. PMID: 40660381.

BibTeX

@article{zhang2025-40660381,
  author  = {Zhang, Jingjing and Kong, Guoqing and Yang, Jinyue and Pang, Lin and Li, Xiubin},
  title   = {{Pathological mechanisms and treatment progression of Alzheimer’s disease}},
  journal = {European journal of medical research},
  year    = {2025},
  doi     = {10.1186/s40001-025-02886-9},
  pmid    = {40660381},
  url     = {https://doi.org/10.1186/s40001-025-02886-9}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review states that current therapies, including recently approved anti-amyloid immunotherapies, have limited clinical efficacy and significant adverse effects, and that no truly disease-modifying therapy exists. It surveys possible future strategies such as tau-targeting and anti-inflammatory agents but does not report a proven treatment or cure.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 4 of 5; Impact for its field and year 6 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 47 of 100.47 of 100 points earned53 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (European journal of medical research)
Journal's citation record 1 / 4 European journal of medical research: journal h-index 80 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 83 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 27.7 citations a year over 3 year(s) since 2025
Impact for its field and year 6 / 6 Cited 45.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 3 / 4 Cited 83 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Xiubin Li: h-index 5 (OpenAlex, whole career)
Institution's track record 0 / 3 Qingdao University: institution h-index 430 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40660381)
Free to read 2 / 2 Free to read
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 27.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Disease mechanisms from nearby years

Also in Disease mechanisms

128 studies in the library are filed under Disease mechanisms with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disease mechanisms hub.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →